Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)